|
13 Apr 2025 |
Krishna Institute
|
Consensus Share Price Target
|
616.75 |
692.23 |
- |
12.24 |
buy
|
|
|
|
|
27 Feb 2025
|
Krishna Institute
|
Geojit BNP Paribas
|
616.75
|
622.00
|
531.60
(16.02%)
|
Target met |
Buy
|
|
|
|
|
11 Feb 2025
|
Krishna Institute
|
Khambatta Securities
|
616.75
|
646.00
|
604.05
(2.10%)
|
Target met |
Hold
|
|
|
? Krishna Institute of Medical Sciences (KIMS) reported a robust 29.7% y-o-y increase in total income to Rs 790.2 crore in 3Q FY25. ? Calculated blended occupancy rate (basis total bed capacity) was 50.7% in 3Q FY25, compared to 56.8% in 2Q FY25.
|
|
10 Feb 2025
|
Krishna Institute
|
Axis Direct
|
616.75
|
710.00
|
612.55
(0.69%)
|
15.12 |
Buy
|
|
|
We maintain our BUY rating on the stock with a target price of Rs 710/share
|
|
10 Feb 2025
|
Krishna Institute
|
Edelweiss
|
616.75
|
683.00
|
612.55
(0.69%)
|
10.74 |
Buy
|
|
|
Capacity expansion to drive growth
|
|
10 Feb 2025
|
Krishna Institute
|
Prabhudas Lilladhar
|
616.75
|
725.00
|
612.55
(0.69%)
|
17.55 |
Buy
|
|
|
|
|
09 Feb 2025
|
Krishna Institute
|
ICICI Securities Limited
|
616.75
|
630.00
|
642.25
(-3.97%)
|
Target met |
Hold
|
|
|
Krishna Institute of Medical Sciences’ (KIMS) Q3FY25 revenue was in-line while EBITDA and PAT were dragged by seasonality and its new Nashik hospitals. KIMS’ hospitals in Telangana/Andhra Pradesh grew a robust 26.1%/27.8% YoY. In Q3FY25, it commenced operations at its 325-bed hospital in Nashik (EBITDA loss of INR 50mn in Q3FY25), which is likely to break even by Q3FY26.
|
|
07 Feb 2025
|
Krishna Institute
|
Emkay
|
616.75
|
750.00
|
642.25
(-3.97%)
|
21.61 |
Buy
|
|
|
KIMS’s Q3FY25 revenues were ahead of Street/our estimates, while profitability lagged owing to certain write-offs in Maharashtra and AP clusters, and losses in the Nashik hospital.
|
|
13 Nov 2024
|
Krishna Institute
|
Khambatta Securities
|
616.75
|
601.00
|
554.20
(11.29%)
|
Target met |
Buy
|
|
|
Krishna Institute of Medical Sciences (KIMS) reported a robust 19.4% y-o-y increase in Total Income during 2QFY25, reaching Rs 782.3 crore. Calculated blended occupancy rate (basis total bed capacity) was 49.7% in 2Q FY25, compared to 47.8% in 1Q FY25.
|
|
12 Nov 2024
|
Krishna Institute
|
Axis Direct
|
616.75
|
615.00
|
554.55
(11.22%)
|
Target met |
Buy
|
|
|
we maintain a BUY rating with a target price of Rs 615/share with a valuation of 21x EV/EBITDA for Sep 27E. The TP implies an upside potential of 10% from the CMP.
|
|
12 Nov 2024
|
Krishna Institute
|
Edelweiss
|
616.75
|
630.00
|
554.55
(11.22%)
|
Target met |
Buy
|
|
|
Capacity expansion to drive growth
|
|
24 Sep 2024
|
Krishna Institute
|
Khambatta Securities
|
616.75
|
572.00
|
552.10
(11.71%)
|
Target met |
Hold
|
|
|
Krishna Institute of Medical Sciences (KIMS) reported healthy y-o-y growth in 1Q FY25 with consolidated operating revenues increasing by 13.8% to Rs 693 crore. Calculated blended occupancy rate (basis total bed capacity) was 49.8% in 1Q FY25, compared to 51.4% in 4Q FY24.
|
|
20 Aug 2024
|
Krishna Institute
|
Geojit BNP Paribas
|
616.75
|
|
474.64
(29.94%)
|
Pre-Bonus/ Split |
Hold
|
|
|
|
|
09 Aug 2024
|
Krishna Institute
|
Axis Direct
|
616.75
|
2500.00
|
2234.60
(-72.40%)
|
Target met |
Buy
|
|
|
We have BUY on the stock
|
|
08 Aug 2024
|
Krishna Institute
|
Edelweiss
|
616.75
|
2560.00
|
2191.50
(-71.86%)
|
Target met |
Buy
|
|
|
Capacity expansion to drive growth
|
|
18 Jun 2024
|
Krishna Institute
|
Prabhudas Lilladhar
|
616.75
|
2200.00
|
2040.10
(-69.77%)
|
Target met |
Buy
|
|
|
|
|
06 Jun 2024
|
Krishna Institute
|
Geojit BNP Paribas
|
616.75
|
2164.00
|
1884.25
(-67.27%)
|
Target met |
Accumulate
|
|
|
|
|
20 May 2024
|
Krishna Institute
|
Edelweiss
|
616.75
|
2193.00
|
1952.20
(-68.41%)
|
Target met |
Buy
|
|
|
Capacity expansion to drive growth
|
|
19 May 2024
|
Krishna Institute
|
ICICI Securities Limited
|
616.75
|
2315.00
|
1952.20
(-68.41%)
|
Target met |
Buy
|
|
|
Krishna Institute of Medical Sciences’ (KIMS) Q4FY24 was below our expectations. One-off refurbishment charge of INR 100mn and higher depreciation of Sunshine Begumpet hospital led to this miss.
|
|
18 May 2024
|
Krishna Institute
|
Axis Direct
|
616.75
|
2100.00
|
1952.20
(-68.41%)
|
Target met |
Buy
|
|
|
We have BUY on stock
|
|
06 Feb 2024
|
Krishna Institute
|
Axis Direct
|
616.75
|
2300.00
|
2133.60
(-71.09%)
|
Target met |
Buy
|
|
|
The Q3FY24 occupancies revealed occupancy softness in KIMS matured hospitals, which constitute 60% of its Telangana and AP revenue. Recommendation BUY
|